华仁药业股份有限公司 2023 年第一季度报告 证券代码：300110 证券简称：华仁药业 公告编号：2023-034 华仁药业股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2、公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度 报告中财务信息的真实、准确、完整。 3、第一季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | | | | （%） | | 营业收入（元） | 403,241,817.91 | 385,486,122.57 | 4.61% | | 归属于上市公司股东的净利 | 41,102,886.41 | 25,039,64 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,619,492,335.02, representing a 3.76% increase compared to ¥1,560,855,394.99 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥180,815,847.76, a significant increase of 38.66% from ¥130,404,876.17 in 2021[17]. - The net profit after deducting non-recurring gains and losses was ¥145,826,156.09, up 18.27% from ¥123,294,353.83 in the previous year[17]. - The cash flow from operating activities improved to ¥217,984,061.64, a turnaround from a negative cash flow of ¥578,520,393.10 in 2021, marking a 137.68% increase[17]. - The total assets at the end of 2022 were ¥5,162,515,249.64, down 8.49% from ¥5,641,539,633.06 at the end of 2021[17]. - The basic earnings per share for 2022 increased to ¥0.153, a rise of 39.09% compared to ¥0.110 in 2021[17]. - The weighted average return on equity for 2022 was 7.39%, up from 5.64% in 2021, indicating improved profitability[17]. - The company reported a net profit of ¥57,604,773.99 in Q4 2022, contributing to a total annual net profit growth[19]. - The company’s net profit margin improved to 11.20%, an increase of 2.61 percentage points compared to the previous year[48]. - The company achieved a 31.25% year-on-year increase in drug sales, totaling 5.09 million bottles (bags/sticks) in 2022[43]. Dividend and Profit Distribution - The company reported a profit distribution plan, proposing a cash dividend of 0.21 RMB per 10 shares, based on a total of 1,182,212,982 shares[4]. - The company approved a cash dividend of RMB 0.21 per 10 shares, totaling RMB 24,826,472.62 for the fiscal year 2022[145]. - The cash dividend accounted for 100% of the total profit distribution amount[145]. - The company reported a distributable profit of RMB 383,704,705.46 for the period[145]. - There were no stock dividends or capital reserve transfers to increase share capital during this period[145]. Market and Industry Insights - The Chinese pharmaceutical market is expected to reach a scale of 2,287.3 billion yuan by 2025, with a compound annual growth rate (CAGR) of 9.6% from 2020 to 2025[27]. - The average price reduction for selected drugs in the first seven rounds of national centralized procurement reached 48%, with a total of 294 varieties covered[27]. - The sales scale of China's medical device market reached 772.1 billion yuan in 2020, growing by 21.8% year-on-year, with a CAGR of 22.85% since 2005[30]. - The market size of the pharmaceutical packaging materials industry in China was 135.86 billion yuan in 2021, with a year-on-year growth of 16%[30]. - The consumption volume of large-volume parenterals is projected to reach approximately 11.7 billion bottles (bags) by 2025, showing a slow growth trend[31]. Research and Development - The company has a comprehensive product structure covering various forms of injections, including large-volume and small-volume preparations, tablets, capsules, and granules[36]. - The company has been recognized multiple times as one of the "Top 100 Pharmaceutical Industries in China" and "Top 100 Chemical Pharmaceutical Enterprises in China"[36]. - The company has implemented electronic drug registration applications starting January 1, 2023, to improve review and approval efficiency[35]. - The company achieved a sales volume of 509 million units (bottles/bags/sticks) in 2022, representing a year-on-year growth of 31.25%[63]. - The company has accumulated 503 patents by the end of the reporting period, indicating a strong focus on innovation[53]. Corporate Governance and Compliance - The company has established a governance structure with a board of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[105]. - The company has established a supervisory board consisting of 3 members, including 1 employee supervisor, complying with legal requirements[106]. - The company maintains strict information disclosure practices, ensuring timely and fair access to information for all shareholders through designated channels[106]. - The company emphasizes compliance and risk management, establishing a comprehensive risk management system to enhance awareness among all employees[108]. - The company operates independently from its controlling shareholders in terms of assets, personnel, finance, and business operations, ensuring a complete business system[109]. Environmental and Social Responsibility - The company adheres to various environmental protection laws and regulations, emphasizing sustainable development[154]. - The company has implemented a comprehensive environmental management system and has not experienced any environmental pollution incidents since its establishment[163]. - The company donated 22,800 N95 masks and 20,000 surgical masks to support pandemic prevention efforts in March and April 2022[164]. - The company has been recognized as a "Qingdao City 'Check and Promote' Activity Outstanding Unit" for its environmental protection management in 2021-2022[163]. - The company has established an emergency response plan for environmental incidents, which is regularly updated[157]. Strategic Initiatives and Future Outlook - The company plans to further expand its market presence and enhance product offerings through ongoing research and development initiatives[58]. - The company aims to enrich its product line and improve market share through the approval of new specifications for existing products, such as the addition of a 1ml specification for Caffeine Citrate Injection[72]. - The company is focusing on digital transformation and establishing a comprehensive sales network to increase market penetration and customer engagement[95]. - The company plans to create new billion-yuan regions and products in 2023, focusing on high-value, high-margin products in therapeutic areas such as respiratory and narcotic medicine[94]. - The future outlook remains positive, with a revenue guidance of 1.3 billion for 2023, reflecting a growth target of 20%[115].

参与方式一：在微信小程序中搜索"华仁药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"华仁药业投资者关系"小程序，即可参与交 流。 证券代码：300110 证券简称：华仁药业 公告编号：2023-018 华仁药业股份有限公司 关于举行 2022 年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载，误导性陈述或重大遗漏。 华仁药业股份有限公司（以下简称"公司"）2022 年年度报告已于 2023 年 3 月 25 日在巨潮资讯网（http://www.cninfo.com.cn/）上披露。为便于广大投资者 进一步了解公司 2022 年度经营情况，公司定于 2023 年 4 月 7 日（星期五）15:00- 17:00 在"华仁药业投资者关系"小程序举行 2022 年度业绩说明会。本次业绩说明 会将采用网络远程的方式举行，投资者可登陆"华仁药业投资者关系"小程序参与 互动交流。为广泛听取投资者的意见和建议，本次业绩说明会提前向投资者征集 问题，提问通道自公告发出之日起开放，公司将在 2022 年度业绩说明会上对投 资者普遍关注的问题进行交 ...

证券代码：300110 证券简称：华仁药业 编号：2014-010 华仁药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|--------------------------------|------------------------------------------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 民生证券曹阳、华商基金陈恒、华鑫证券孙志达、富安达基金李 | | 及人员姓名 | 守峰 | | | 时间 | 9:00-10：00 | | | 地点 | 公司第六会议 | | | 上市公司接待 | 董事会秘书 龚凌 | | | 人员姓名 | | | | 投资者关系活 | 问：公司上半年的经营情况如何？ | | | 动主要内容介 | | 答：今年上 ...

证券代码：300110 证券简称：华仁药业 编号：2014-011 华仁药业股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|--------------------------------|-----------------------------------------------------------------| | | | | | 投资者关系活 | √ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 融通基金 姚昆 | | | 及人员姓名 | | | | 时间 | 14:30-15：30 | | | 地点 | 公司第六会议室 | | | 上市公司接待 | 董事会秘书 龚凌 | | | 人员姓名 | 投资经理： 班文溥 | | | 投资者关系活 | 问：公司上半年的经营情况如何？ | | | 动主要内容介 | | 答：今年上半年公司整体发展平稳，收入 ...

Group 1: Company Overview and Investor Relations - The investor relations activity included a visit to the company's infusion culture museum and a speech by Chairman Liang Fuyou [1][2] - The event was attended by over 70 investors and 10 media representatives, along with leaders from the Shenzhen Stock Exchange [1] Group 2: Industry Context and Company Strategy - The pharmaceutical industry experienced an average annual growth rate of 22.77% from 2004 to 2013, but growth slowed in 2014, with a total output value of 1,770.5 billion yuan, a year-on-year increase of 15.6%, down 3.6% from 2013 [2] - The acquisition of Hongta Innovation Investment Co., Ltd. aims to leverage capital markets for industry integration and transformation [2] Group 3: Future Development Plans - Future plans include strengthening the infusion business, expanding peritoneal dialysis products and services, and exploring new pharmaceutical packaging [3] - As of the end of Q1, the number of new patients increased by 24.94% compared to Q4 2014, with a shipment volume increase of 192.5% [3] Group 4: Restructuring and Market Expansion - The restructuring process is progressing smoothly, with necessary materials submitted for approval to state asset management [4] - The company is pursuing TGA certification to enable sales in over 20 countries and is analyzing market conditions along the "Belt and Road" initiative [4]

证券代码：300110 证券简称：华仁药业 华仁药业股份有限公司投资者关系活动记录表 编号：2015-004 | --- | --- | --- | |-------------------|--------------------------|-------------------------------------------------------| | | | | | 投 资 者 关 系 活 | √ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ 现场参观 | | | | □ 其他 | | | 参 与 单 位 名 称 | 中金基金：王雁杰 | | | 及人员姓名 | | 中金公司：李梦遥、张翔、曹晏、易俊津 | | 时间 | 2015 年 7 月 23 | 日下午 15：00-16 ： 00 | | 地点 | 青岛市高科技工业园株洲路 | 187 号华仁药业第一会议室 | | 上 市 公 司 接 待 | 董事会秘书：龚凌 | | | 人员姓名 | 投资经理：班文溥 | | | 投 资 者 关 系 活 | 问题 ...